Improving the power of drug toxicity measurements by quantitative nuclei imaging

2Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Imaging-based anticancer drug screens are becoming more prevalent due to development of automated fluorescent microscopes and imaging stations, as well as rapid advancements in image processing software. Automated cell imaging provides many benefits such as their ability to provide high-content data, modularity, dynamics recording and the fact that imaging is the most direct way to access cell viability and cell proliferation. However, currently most publicly available large-scale anticancer drugs screens, such as GDSC, CTRP and NCI-60, provide cell viability data measured by assays based on colorimetric or luminometric measurements of NADH or ATP levels. Although such datasets provide valuable data, it is unclear how well drug toxicity measurements can be integrated with imaging data. Here we explored the relations between drug toxicity data obtained by XTT assay, two quantitative nuclei imaging methods and trypan blue dye exclusion assay using a set of four cancer cell lines with different morphologies and 30 drugs with different mechanisms of action. We show that imaging-based approaches provide high accuracy and the differences between results obtained by different methods highly depend on drug mechanism of action. Selecting AUC metrics over IC50 or comparing data where significantly drugs reduced cell numbers noticeably improves consistency between methods. Using automated cell segmentation protocols we analyzed mitochondria activity in more than 11 thousand drug-treated cells and showed that XTT assay produces unreliable data for CDK4/6, Aurora A, VEGFR and PARP inhibitors due induced cell size growth and increase in individual mitochondria activity. We also explored several benefits of image-based analysis such as ability to monitor cell number dynamics, dissect changes in total and individual mitochondria activity from cell proliferation, and ability to identify chromatin remodeling drugs. Finally, we provide a web tool that allows comparing results obtained by different methods.

References Powered by Scopus

Complex heatmaps reveal patterns and correlations in multidimensional genomic data

5413Citations
N/AReaders
Get full text

The NCI60 human tumour cell line anticancer drug screen

2213Citations
N/AReaders
Get full text

Defining a Cancer Dependency Map

1684Citations
N/AReaders
Get full text

Cited by Powered by Scopus

PAMAM/miR-144 nanocarrier system inhibits the migration of gastric cancer by targeting mTOR signal transduction pathway

0Citations
N/AReaders
Get full text

Systematic Comparison of FBS and Medium Variation Effect on Key Cellular Processes Using Morphological Profiling

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Mikheeva, A. M., Bogomolov, M. A., Gasca, V. A., Sementsov, M. V., Spirin, P. V., Prassolov, V. S., & Lebedev, T. D. (2024). Improving the power of drug toxicity measurements by quantitative nuclei imaging. Cell Death Discovery, 10(1). https://doi.org/10.1038/s41420-024-01950-3

Readers over time

‘2402468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 1

50%

Researcher 1

50%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 4

80%

Engineering 1

20%

Article Metrics

Tooltip
Mentions
News Mentions: 2

Save time finding and organizing research with Mendeley

Sign up for free
0